Brokerages Set Abeona Therapeutics Inc. (NASDAQ:ABEO) Price Target at $20.00

Abeona Therapeutics Inc. (NASDAQ:ABEO) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $20.00.

ABEO has been the topic of several analyst reports. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings downgraded Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research note on Monday, October 13th.

Insider Buying and Selling

In other news, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $4.74, for a total transaction of $71,100.00. Following the completion of the sale, the director directly owned 62,252 shares of the company’s stock, valued at approximately $295,074.48. The trade was a 19.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $5.31, for a total transaction of $132,750.00. Following the transaction, the chief executive officer owned 1,164,818 shares of the company’s stock, valued at approximately $6,185,183.58. The trade was a 2.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 40,249 shares of company stock valued at $205,217 in the last quarter. 6.90% of the stock is owned by insiders.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $25,000. Legal & General Group Plc acquired a new stake in Abeona Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Abeona Therapeutics during the third quarter worth approximately $37,000. Legato Capital Management LLC purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $57,000. Finally, Riverwater Partners LLC acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at $62,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Trading Down 1.7%

Shares of ABEO stock opened at $5.22 on Tuesday. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.54. The company has a 50 day moving average price of $4.91 and a 200 day moving average price of $5.69. The stock has a market capitalization of $282.88 million, a P/E ratio of 4.24 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. Equities research analysts predict that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.